SOUTH SAN FRANCISCO, Calif., Oct. 1, 2012 (GLOBE NEWSWIRE) -- diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that Brian E. Ward, Ph.D., Chief Executive Officer, is scheduled to present at the SeeThruEquity Fall 2012 Smallcap and Microcap Investor Conference at the Cornell Club in New York. Dr. Ward will provide a corporate overview and update and will be available to conduct one-on-one meetings with investors. Event: SeeThruEquity Fall 2012 Smallcap and Microcap Investor Conference Date: October 3, 2012 Time: 1:00 pm ET A live webcast of the presentation will be accessible on diaDexus' website at www.diadexus.com . Please go to the website a few minutes early, as it may be necessary to download audio software to hear the presentation. A replay of the webcast will also be available after the conference concludes. About diaDexus, Inc. diaDexus, Inc., based in South San Francisco, California, is developing and commercializing proprietary cardiovascular diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC® Test ELISA Kit is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. The company's PLAC® Test for Lp-PLA2 Activity, a CE-marked test, is an indicator of atherosclerotic cardiovascular disease, the #1 cause of death in Europe. diaDexus is ISO 13485 certified and is manufacturing the PLAC Test for Lp-PLA2 Activity on-site. For more information, please visit the company's website at www.diaDexus.com.
CONTACT: Company Contacts: diaDexus, Inc. Brian E. Ward, Ph.D., CEO Jean-Frederic Viret, Ph.D., CFO 650-246-6400 investors.diadexus.com Investor Relations: The Ruth Group Nick Laudico / Zack Kubow 646-536-7030 / 7020 email@example.com firstname.lastname@example.org